Invivyd Inc. (IVVD) is entering 2026 with strong momentum, driven by expanding revenues from its authorized COVID-19 antibody PEMGARDA (pemivibart), a robust cash position, and a pipeline of next-generation monoclonal antibodies targeting COVID-19, RSV, and measles.
With the pivotal DECLARATION Phase 3 trial of VYD2311 underway, Fast Track designation secured, and IND readiness for RSV candidate VBY329 expected later this year, Invivyd is positioning itself as a leader in antibody-based prophylaxis for infectious diseases.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.